One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Cytokinetics stock cleared that benchmark Monday, with a jump from 78 to 83 Monday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history reveals that the best stocks tend to have an RS Rating north of 80 as they begin their biggest climbs.
Is Cytokinetics Stock A Buy?
Cytokinetics stock has climbed more than 5% past a 47.90 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Cytokinetics showed 0% EPS growth in its most recent report, while sales growth came in at 26,608%.
The company holds the No. 222 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
